Anti-focosylceramide monoclonal antibody
US5331093A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 27, 1992 |
| Grant date | Jul 19, 1994 |
| Priority date | — |
| Expiry date | May 27, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates to a monoclonal antibody PC47H specifically recognizing fucosylceramide derived from a ceramide-mono-glycoside fraction of neutral glycolipid extracted and purified from human cancer tissues and having properties such as belonging to IgM and showing reactivity to neither of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast nor cell lines derived from leukemia, hepatoma, breast cancer and neuroblastoma but to cell lines derived from lung cancer, stomach cancer, colon cancer and pancreas cancer; a hybridoma having ability to produce the aforementioned monoclonal antibody; a method for manufacturing the aforementioned monoclonal antibody which comprises immunizing an animal with a neutral glycolipid fraction extracted from human pancreas cancer, fusing animal cells with myeloma cells to generate hybridomas, cloning the hybridomas, selecting clones which produce monoclonal antibodies which specifically recognize fucosylceramide and then using the clones to manufacture the monoclonal antibody; and a diagnostic aid of cancers such as lung cancer, stomach cancer, colon cancer and pancreas cancer containing the aforementioned monoclonal antibod…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.